

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification 4 : C12N 15/00, 7/00, C07H 21/04 A61K 39/275 // (C12N 7:00 C12R 1:91)</p>	<p>A1</p>	<p>(11) International Publication Number: WO 89/ 07644</p> <p>(43) International Publication Date: 24 August 1989 (24.08.89)</p>
<p>(21) International Application Number: PCT/AU89/00055</p> <p>(22) International Filing Date: 10 February 1989 (10.02.89)</p> <p>(31) Priority Application Number: PI 6721</p> <p>(32) Priority Date: 12 February 1988 (12.02.88)</p> <p>(33) Priority Country: AU</p>		
<p>(71) Applicant (for all designated States except US): COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANIZATION [AU/AU]; Lime-stone Avenue, Campbell, ACT 2601 (AU).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only) : BOYLE, David, Bernard [AU/AU]; 31 Christies Road, Leopold, VIC 3224 (AU). KUMAR, Sharad [IN/AU]; 2/9 Stafford Street, Herne Hill, VIC 3218 (AU).</p>		
<p>(74) Agent: PHILLIPS ORMONDE & FITZPATRICK; 367 Collins Street, Melbourne, VIC 3000 (AU).</p> <p>(81) Designated States: AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), SE (European patent), US.</p> <p>Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>		
<p>(54) Title: POX VIRUS VECTORS</p>		
<div style="font-family: monospace; font-size: 0.9em;"> <pre> 5'-A T T T A G T A T C C T A A A A T T G A A T T G T A A T T A T C G A T A A T A A A T →Early 5'-A T T T A T T A T C G A T A A T T A C A A T T G A A T T T T A G C A T A C T A A A T →Late </pre> </div>		
<p>(57) Abstract</p> <p>A gene sequence including a first promoter for the expression of a major early fowlpox virus (FPV) protein. In a preferred aspect, the gene sequence further includes a second promoter for the expression of a late fowlpox virus protein in opposite orientation to said first promoter. The promoter is useful in developing FPV based vectors for the delivery of vaccine antigens preferably to poultry, and as a tool to study the temporal regulation of poxvirus genes. The invention also offers methods useful in the construction of recombinant fowlpox viruses or related avian poxviruses, which methods are characterized by the introduction of foreign DNA into the fowlpox virus or into virus DNA sequences, which sequences are able to use native FPV promoter regions.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland				

POX VIRUS VECTORS

This invention relates to recombinant vectors and their construction, and in one aspect this invention relates to recombinant fowlpox virus vectors and use thereof.

Poxviruses are large DNA viruses which replicate within the cytoplasm of infected cells. The vaccinia virus is the most widely studied member of the poxvirus family and has been widely used to express a number of foreign genes inserted into the vaccinia virus genome. In recent years, recognition of non-essential regions of the vaccinia virus genome, followed by mapping and nucleotide sequence determination, has made it possible to insert and express a wide variety of foreign genes through the medium of recombinant vaccinia viruses. Such recombinant vaccinia viruses have the potential to deliver vaccine antigens to a variety of animal species. However, for faithful expression of an inserted gene, it is important to position the gene near unique viral promoter regions.

A recognised problem resides in a risk of cross species infection and therefore the spread of disease from one animal species to another through the widespread use of vaccinia virus in animals. Thus, the construction of recombinants based on host specific poxviruses is desirable, e.g. fowlpox virus for poultry or ORF for sheep vaccines. Although promoter sequences have been described for a number of early and late genes of vaccinia viruses, little is known about promoter regions in other pox viruses. In order to construct host specific live viral vaccines, it is of fundamental importance that the molecular biology of those viruses, and in particular the biology of transcriptional

control elements or promoter region(s) in the pox virus be understood. Therefore, it is necessary to characterise and isolate these regions before utilising them in suitable recombinant vectors. Such vectors show great potential for the manufacture of viral vaccines and the like.

Accordingly, it is an object of the present invention to overcome, or at least alleviate, one or more of the deficiencies and/or difficulties related to the prior art.

Accordingly, in a first aspect of the present invention there is provided a gene sequence including a first promoter for the expression of a major early fowlpox virus protein.

In a preferred aspect of the present invention, the gene sequence further includes a second promoter for the expression of a late fowlpox virus protein in opposite orientation to said first promoter.

The gene sequence may be approximately 40 base pairs in length, consisting of two promoter elements in opposite orientation to each other.

As stated above, this promoter sequence, in its preferred form, is characterised in that it has a major early function and a late function in opposite orientation to the early function. The early function of the promoter compares well with the strongest known promoter of vaccinia virus (PL11). Because of the strength of this promoter and its unique bidirectional nature, it has important applications in the construction of both vaccinia (VV) and FPV vectors and other recombinant poxviruses for the delivery of foreign antigens. Its small and defined size makes it a versatile DNA element which may express two foreign genes of interest

simultaneously in a pox virus expression system as described below. Since its early function compares well in strength with PL11, a VV promoter widely used for expression of foreign genes during late stages of virus growth cycle, it may be a promoter of choice when high levels of expression is required during early stages of virus growth. Its promoter strength is 3-4 times greater than the VV P7.5 promoter which has been widely used, to date, to express genes in recombinant VV, FPV and other poxviruses (for a review see Moss and Flexner, 1987). The gene sequence may be particularly useful to induce cytotoxic T-lymphocyte (CTL) response to an expressed antigen since late promoter expressed gene products appear not be recognised by CTL (Coupar et al, 1986). Being a FPV native promoter, it may be a promoter of choice in developing FPV based vectors for the delivery of vaccine antigens preferably to poultry.

Finally, because of its small and defined size and its unique structure, it may provide an important tool to study the temporal regulation of poxvirus genes.

In a further preferred aspect of the present invention there is provided a gene sequence including a first promoter for the expression of a major early fowlpox virus protein.

Accordingly, in a preferred aspect there is provided a plasmid selected from plasmids pSK06 and pSK07 as hereinbefore described.

Samples of purified DNA containing the plasmid pSK06 were deposited with the Australian Government Analytical Laboratories of 1 Suakin Street, Pymble, New South Wales, 2073, Australia, on 9th February, 1989 and have

received the deposition number N89/004621.

The viral vector or derivative thereof may be constructed using a suitable plasmid cloning vector. Suitable plasmid cloning vectors include pUC8, pUC12, M13 - mp8 and - mp9.

The native promoter region and fragment of foreign DNA may be flanked by DNA of non-essential regions of the FPV genome. It will be understood that the use of DNA constructs employing native promoter regions of the fowlpox virus not only makes possible the provision of highly host specific viruses, but also provides for a far more efficient virus in terms of its translational efficiency relative to other recombinant pox viruses, all of which to date have employed foreign promoter regions from other sources to initiate expression of selected genes, e.g. promoter regions from a vaccinia virus source.

Accordingly in a preferred aspect, there is provided
a viral vector including a
portion of the genome of a vector virus;
a gene sequence including

a first promoter for the expression of an early
fowlpox virus protein; and

a second promoter for the expression of a late
fowlpox virus protein in opposite orientation to
said first promoter; and

a first DNA sequence coding for a first foreign gene
of interest and under the control of the first promoter.

Preferably the first foreign DNA sequence codes for
a first antigen characteristic of an avian disease.

In a preferred embodiment of this aspect of the present invention the viral vector includes alternatively or in addition to said first DNA sequence a second DNA sequence coding for a second foreign gene of interest and under the control of the second promoter.

Preferably the second foreign DNA sequence codes for a second antigen characteristic of an avian disease.

In a particularly preferred form, the portion of the genome of a virus is a portion of the fowlpox virus genome or vaccinia virus genome.

In a preferred form the plasmid cloning vector may include a DNA sequence of a non-essential region of the FPV genome into which region the suitable native promoter region and fragments of foreign DNA may be inserted.

In this form the native promoter region and promoter of foreign DNA may be flanked by DNA of a non-essential region of the FPV genome.

Accordingly, the viral vector according to this aspect of the present invention may be utilised in the preparation of vaccines, preferably vaccines against avian disease.

In a further aspect of the present invention there is provided a process for the preparation of a viral vector which process includes

providing

a viral DNA from a fowlpox virus; and

a plasmid cloning vector;

constructing a genomic library from the viral DNA;

identifying a gene sequence from the genomic DNA library, said gene sequence including

a first promoter for the expression of a major early fowlpox virus protein; and

a second promoter for the expression of a late fowpox virus protein in opposite orientation to said first promoter; and

inserting the gene sequence into a suitable site in the plasmid cloning vector.

In a preferred aspect of the process of the present invention the process may include the step of mapping and sequencing a suitable native promoter region.

In a further preferred aspect of the process of the present invention may further include providing a second suitable plasmid cloning vector

and subcloning a segment of the first plasmid cloning vector including the native promoter region into the second suitable plasmid cloning vector.

The preferred process may further include further sequencing of the native promoter region.

In a preferred form of the process of the present invention the process may include

providing

a first suitable plasmid cloning vector,

a suitable native promoter region,

a first segment of DNA encoding a non-essential region of FPV genome,

a second segment of foreign DNA;

cloning the first segment into the suitable plasmid cloning vector,

cloning the native promoter region into the suitable plasmid cloning vector within the first segment of DNA,

cloning the second segment of foreign DNA into the suitable plasmid cloning vector within the first segment of DNA.

It will be understood in this preferred manner the native promoter region and second segment of foreign DNA may be inserted into viable FPV at a previously established region by virtue of the flanking non-essential region of the FPV genome created as described above.

The thus formed sequence may be inserted into FPV virus infected cells utilising any suitable technique for example homologous recombination.

It is to be understood that while the invention hereinbelow describes the isolation and characterisation of early gene of fowlpox virus and the insertion of fowlpox promoter sequences into a plasmid vector, the technology described is equally applicable to the isolation and characterisation and insertion of other native animal pox virus promoter regions into suitable recombinant plasmids. These plasmids may then be utilised to produce animal pox virus vaccines.

In the first stage of mapping and sequence of the promoter sequence, in a preferred identification early mRNA's coded by the FPV genome was undertaken. Such identification lead to a major approximately 1.0kb transcript which was mapped to an approximate 1.5 kb ClaI fragment.

The 1.5 kb fragment was cloned into PUC8 and M13 vectors and sequenced.

Accordingly in a preferred embodiment of the present invention there is provided a fowlpox virus vector including an approximate 1.5kb ClaI fragment cloned into a suitable

plasmid or bacteriophage cloning vector. Such cloning vector may include pUC8, pUC12, M13-mp8 and mp9.

Further identification may be undertaken utilising fragments of the clone which may be sub-cloned into other plasmids and sequenced. The dideoxy chain termination method may be used.

Accordingly, in a still further embodiment of the present invention comprises a gene sequence including a late RNA start site and an early RNA start site separated by a short sequence of DNA. The gene sequence may constitute a bidirectional promoter cassette.

In a further aspect, the invention may be utilised to provide an avian disease vaccine comprising recombinant fowlpox virus wherein at least a first foreign DNA sequence encoding an antigen characteristic of the said avian disease has been inserted into a suitable gene of the fowlpox virus or in virus DNA sequences controlling expression of said gene, and under the control of at least a first native fowlpox virus promoter region or regions. Preferably two foreign DNA sequences may be included under the control of a bidirectional promoter element on either side in opposite orientation.

It is envisaged that in accordance with the present invention vaccines may become available for protection against a wide variety of avian diseases such as those caused by viruses, bacteria, protozoa, metazoa, fungi and other pathogenic organisms, by insertion of DNA sequences encoding appropriate antigens characteristic of these diseases into the FPV genome as broadly outlined above.

In one aspect, the present invention now makes

possible the construction of a biologically safer range of host specific recombinant avian vaccines than hitherto obtainable, which vaccines include native promoter regions of the fowl pox virus.

This invention therefore also offers methods useful in the construction of recombinant fowlpox viruses or related avian poxviruses, which methods are characterized by the introduction of foreign DNA into the fowlpox virus or into virus DNA sequences, which sequences are able to use native FPV promoter regions.

The present invention will now be more fully described with reference to the accompanying examples. It should be understood, however, that the following description is illustrative only and should not be taken in any way as a restriction on the generality of the invention described above.

In the figures

FIGURE 1 is a restriction map of PstI fragment F of fowlpox virus genome and mapping of major E-gene within it. The directions of two ORF's within the 1.5kb ClaI fragment and one upstream of it are indicated by arrows. ORF1 and 3 represent two late genes while ORF2, the major early gene.

FIGURE 2 is a mapping of FPV-PstI fragment F coded early transcripts by northern blot analysis. Total cellular RNA isolated from virus infected cells incubated in presence of AraC was hybridised to gel purified nick translated ClaI fragments of PstI fragment F. A, 1.5 kb; B, 2.0kb; C, 3.0kb; D, 4.0kb and E, 4.8kb. RNA was electrophoresed on 1.2% agarose, 5.4% formaldehyde denaturing gels and blotted onto Hybond-N nylon membranes prior to hybridization to

³²P-labelled nick translated probes.

FIGURE 3 is a sequence of 1.5 kb ClaI fragment and the region around it. Sequence was obtained from both strands by dideoxy method using EcoRI and HindIII subclones of 1.5 kb ClaI fragment in M13. The region upstream and downstream of ClaI sites was sequenced using synthetic primers on ss DNA templates from M13 clones containing the 3.7kb SalI fragment (see Figure 1). The translation start and termination sites for the two ORF's, and location of primers used for S1 nuclease analyses are indicated. The RNA start sites for all three genes are indicated by dotted lines. The two promoter element (E and L) described in the text is boxed in this figure.

FIGURE 4 is a S1 nuclease analysis of 1.5kb ClaI fragment. Two ss-M13 DNA clones containing the complementary strands of the ClaI fragments (in mp8 and mp9 respectively) were hybridised to total cellular RNA from uninfected host cells (lanes 1 and 4) or FPV infected cells incubated in the presence (lanes 2 and 5) or absence (lanes 3 and 6) of AraC, followed by treatment with S1 nuclease. Protected fragments were fractionated on 1% alkaline agarose gels, transferred to nylon membranes and hybridised to nick translated ³²P-labelled ClaI fragment. M13 mp8 clone (lanes 1-3) is early RNA like strand, while M13 mp9 clone (lanes 4-6) contains sequence complementary to early gene RNA.

FIGURE 5 is a mapping of the 5'-end of the ORF1 coded RNA. Total cellular RNA from uninfected CES cells (Lane 2) or FPV infected cells in the presence (lane 3) or absence (lane 4) of AraC was hybridized to ³²P-labelled ss probe (lane 1). For preparation of probes, 2 synthetic

primers complementary to ORF1, 424 (Primer 1) and 482 bp (Primer 2) upstream of the ClaI site were extended in the presence of ^{32}P -dCTP on ss-M13 DNA clone (M13-Sal 3.7), cut with SalI and relevant DNA fragments isolated from sequencing gels. DNA-RNA hybrids were treated with S1 nuclease and protected fragments ran on 6% sequencing gels alongside a sequencing ladder obtained by same M13 DNA template and primers. Panels A and B represent experiments with primers 1 and 2 respectively. The sequence around the 5'-end of the major protected fragments is shown for the RNA like strand. Technical details of S1 nuclease analysis were according to Davis et al, (1986).

FIGURE 6 is a mapping of the 5'-end of ORF2 coded RNA. ^{32}P -labelled ssDNA probe complementary to RNA like strand was prepared by extending a synthetic primer 124bp upstream of ClaI site on a M13-Sal 3.7 ssDNA clone followed by digestion with EcoRI and isolation of 453 base probe from sequencing gels. Probe (lane 1) was hybridised to RNA isolated from uninfected cells (lane 2), FPV infected cells incubated in presence of 100 ug/ml cycloheximide (lane 3) or 50 ug/ml AraC (lane 4) or without either (lane 5). Following S1 treatment of DNA-RNA hybrids, the protected fragments were analysed on 6% sequencing gel. DNA markers (M) were prepared by ^{32}P -labelling of HpaII cut pBR322 fragments. Sequencing ladder on the left hand side was obtained by using the same primer and template as used for preparation of hybridization probe. Sequence around the 5'-end of protected fragments is shown for the RNA like strand.

FIGURE 7 is a mapping of the 5'-end of ORF3 coded RNA. ^{32}P -labelled ssDNA probe complementary to the RNA was

prepared by extending a synthetic primer 91bp downstream of ClaI site on a M13-Sal 3.7 ssDNA clone containing the RNA like strand followed by digestion with AccI and isolation of 260 base probe from sequencing gels. Rest of the experimental details were as in Figure 5. Lane 1, probe alone; lane 2, uninfected cell RNA; lane 3, early RNA (cycloheximide); lane 4, early RNA (AraC); lane 5, late RNA. Markers (M) are same as in Figure 5. Sequence around two late RNA protected fragments is shown for RNA like strand.

FIGURE 8 is a construction of the plasmids used in transient expression experiments. Polylinker region of pSK06 containing the promoter element (P) in SalI site is shown in panel A. The direction of early and late transcription are indicated and early and late RNA start sites are underlined. In pSK07, from which pSK09 and pSK22 were derived, the orientation of SalI fragment in relation to polylinker, was opposite to that in pSK06; pSK08 and pSK09 were constructed by cloning E. coli LacZ gene into the Bam HI site of pSK06 and pSK07 respectively (B). The sequence around promoter-LacZ junction for pSK08 and pSK09 deletion mutants used in transient expression system is also shown. The basic structure of other plasmids used in experiments detailed in Tablet 3 is shown in panel C. In the figures in panel C, promoter and gene fragments are not proportionate to their actual sizes.

FIGURE 9 is an alignment of early and late promoter elements of FPV.

EXAMPLE 1

Identification and mapping of the major early gene

FPV encoded early mRNA's were detected by

hybridizing total cellular RNA prepared from FPV infected CES cells grown in the presence of AraC to four cloned PstI fragments of the FPV genome. Four fragments E, F, J and M (20.5, 17.3, 12.5 and 5.7 kb respectively) representing approximately 1/6th of the total genome of FPV (Coupar et al, unpublished) were analysed and eleven early transcripts were identified by norther blot analysis of RNA (Table 1), of which four hybridised to fragment F. The restriction enzyme map of fragment F is shown in figure 1. To map the early transcripts within the 17.3 kb fragment F, 5 size fractionated ClaI fragments of 4.8, 4.0, 3.0, 2 x 2.0 and 1.5 kb respectively were hybridized to early RNA (Figure 2). The major RNA transcript (approximately 1.0kb) was mapped to the 1.5 kb fragment. Three other early transcripts of 3.2, 2.3 and 1.2 kb respectively were also detected. The quantity of this transcript is approximately 10 fold higher than any of the other transcripts hybridizing to the four PstI fragments of the FPV genome used in the study.

Sequencing of ClaI fragment

The 1.5kb ClaI fragment was cloned into the AccI site of pUC 8, released as an EcoRI/Hind III fragment and recloned into M13 mp8 and mp9. The EcoRI and HindIII fragments of the clone were also subcloned into M13 vectors and the complete sequence of 1.5 kb ClaI fragment obtained by sequencing both strands is shown in Figure 3. The sequence consisted of two open reading frames (ORF's), one (ORF1) extending beyond the ClaI site (1101 bp) and the other (ORF2) in the opposite orientation (501bp) contained solely within 1.5 kb ClaI fragment. To ascertain which one of these ORF's codes for the early RNA, two single stranded M13 clones

consisting of complementary strands of the 1.5 kb ClaI fragments were hybridized to early and late RNA from FPV infected cells, treated with S1 nuclease, electrophoresed on alkaline denaturing gels, transferred to nylon membranes and hybridised to nick-translated ClaI fragment. The mp8 clone (complementary to ORF1) protected a 1.5 kb late RNA while the mp9 clone (complementary to ORF2) protected one 0.55kb early RNA and two 1.50kb and 0.55kb fragments with late RNA's. This indicated that ORF1 and ORF2 code for a late and an early/late transcript respectively. The 0.55kb protected fragment late in the infection (Figure 4, lane 6) possibly represents the presence of stable early message. The longer protected fragment of 1.5 kb in lane 6 could either be a transcript originating from the same start point as early transcript and terminating downstream of distal ClaI site, or a late transcript originating upstream of proximal ClaI site (upstream of the early gene initiation point). Since pox virus late genes lack defined termination signals, giving rise to transcripts with heterogenous 3' ends (Moss, 1985), the 1.5 kb protected fragment in lane 6 of Figure 4 could have only originated from a late RNA start site near or upstream of the early start site. From S1 nuclease analysis (see below) it was apparent that the former possibility is true.

Analysis of the 5'-end of the ORF1 coded RNA

It was apparent from data presented earlier (Figure 4) that ORF1 codes for a late RNA. In order to determine the 5'-end of this late gene, two synthetic oligomers complementary to late RNA like strand (Primers 1 and 2, Figure 3) were extended on M13 clone consisting of the 3.7 kb

SalI fragment (Figure 1) in the presence of ^{32}P -dCTP. ssDNA probes complementary to late transcript were hybridised to early and late RNA from FPV infected cells followed by S1 nuclease treatment (Figure 5). It is clear from Figure 5 that only late RNA protected the probe and the major protected product mapped to a 'TAAAT' sequence near the translation start site (Figure 3).

Analysis of the 5'-end of the ORF2 coded RNA's

For the 5'-end analysis of the gene, a probe was prepared using a primer (primer 3, Figure 3) upstream of the ClaI site and extending it on a ss-M13-Sal13.7 DNA clone which encompasses the complete ClaI fragment (Figure 1). The 5'-end of the protected fragment by immediately early, early and late RNA mapped to a sequence TAAAT near the ATG of ORF2 (Figure 6). Since there were no late RNA protected fragments of larger size, it appears that both early and late RNA shown in figure 4, initiate at the same start point. This is, to our knowledge, the first poxvirus promoter described where the same initiation site is recognised by RNA polymerase both during early and late stages of infection. However, the immediately early function of the gene appears to be the major aspect of the gene and for this reason and to avoid confusion, this promoter with early/late function has been referred as early promoter in the following text.

Presence of a late promoter function upstream and in opposite orientation to ORF2

The sequencing of DNA upstream of the ClaI site revealed the presence of an ORF starting 35bp from the early start site and in opposite orientation (ORF3, Figure 3). The start of ORF3 consists of a 'TAAAT' motif, suggesting that it

would transcribe a late mRNA. The S1 nuclease analysis of the 5'-end of this late gene revealed that only late RNA protected the probe from S1 digestion (Figure 7). Major products mapped to the predicted 'TAAAT' motif upstream of the ATG while another major product mapped to a sequence 30bp upstream (ATTA). There were several larger protected fragments all the way up to the size of probe and these possibly represent the heterogeneous 3'-ends of late transcript originating from ORF1. Since the late transcript maps to the sequence 30-35bp upstream of the early start site, the sequence between the two start sites constituted a potential bidirectional promoter element, having both early/late and late function in opposite orientations.

40bp of DNA are sufficient for expression of
both early and late genes

In order to assess the promoter activities, DNA sequence comprising of both early and late start sites and the first two amino acid codons (ATG and the following 3 bases) flanked by SalI linkers were synthesized and cloned into the SalI site of pUC12 in both orientations (Figure 8). The first two codons of ORF's were included since the start site of both head to head genes map very close to the translation start site. A BamHI fragment from pGH101 consisting of a LacZ gene of *E.coli* (Herman et al., 1986) was then placed downstream of the promoter element (into the BamHI site) of pUC 12 linker. These vectors were designed in such a way that the ATG of LacZ was in frame with the ATG of the respective promoters (Figure 8). These plasmids were then used in a VV transient expression system to assess the promoter strengths by the levels of B gal expressed (Table

2). The results indicated that high levels of B-gal were expressed by the both early and late promoter elements. The temporal regulation of the promoter was also maintained and thus the early promoter activity was not affected by inclusion of AraC, and inhibition of DNA synthesis, while the late promoter activity was completely abolished (Table 2). Results also show that in CV-1 cells, the activity of early promoter is approximately 5-6 fold higher than that of late promoter. In a mutant of the early promoter where the region between ClaI and PstI site of pSK08 was deleted the activity of the early promoter was almost completely abolished (Table 2). Also deletion of 2bp near the start site of late promoter abolished the activity of the late promoter (Table 2).

Assessment of the activity of FPV - early promoter
relative to vaccinia virus promoters

Two widely used and well characterised promoters of VV, PL11 (late) and P7.5 (early/late) were used in a transient expression system to compare their activity with the FPV-early promoter. Constructs consisting of LacZ under control of PL11 (pDB22-LacZ) and P7.5 (pTP4) have been described and contain the LacZ-promoter chimera, flanked by either the FPV (pDB22-LacZ) or VV (pTP4) TK gene. pDB22-LacZ also contains an E.coli gpt gene under control of P7.5. Analogous plasmid constructs were made using the early promoter and LacZ gene, and used in the transient B-gal expression system. The results are shown in Table 3. It is clear from the data that the transfection of all plasmids result in significant amounts of B-gal activity in the transient expression system.

In pSK18, 20 and 22 where LacZ was placed under control of early-promoter element of FPV, flanked by either VV or FPV TK gene produce comparable B-gal activities. In the presence of AraC, an apparent accumulation of B-gal occurs, as was evident also from data in Table 2. Again the activity of late promoter element of FPV was about 1/5th of the early-promoter activity. When compared with two of the most used promoters of VV, P7.5 and PL11, the early-promoter activity was about 3.5 fold higher than that of P7.5 and approximately same to PL11. Since PL11 is the strongest known promoter of VV, the early FPV promoter is thus equally efficient. It is also clear from the data in Table 2 that the temporal regulation of all the promoters is maintained under transient expression conditions since in all cases, inhibition of DNA synthesis of AraC caused the block in late promoter activity. However, P7.5 an early/late promoter of VV only appeared to work late in the infection in our transient expression system, as has been observed by others (Chakrabarti et al., 1985).

Structure of the FPV promoter element

It is clear from the data presented earlier that only 34bp of DNA sequence between the early and late gene start sites (between 2-ATG's) is sufficient for the transcription of the early and late genes respectively. Since early and late promoters of pox viruses appear to be quite different (Smith et al, 1984) the FPV promoter element could be used in determining the DNA domains required for temporal regulation of pox virus early and late genes. It is evident from the results presented that a mutation near the early start site or within the TAAAT motif of late start site

almost completely abolish their respective transcription function (Table 2). Pox virus late promoters are characterised by a highly conserved 'TAAAT' motif which is an essential cis acting element (Hanggi et al, 1986; Rosel et al, 1986). Thus the late promoter of FPV is similar to other reported pox virus late promoter elements. The interesting aspect of the FPV promoter element however is that early start site also maps to a TAAAT motif. The 5'- 3' alignment of the two strands of FPV promoter element show remarkable degree of similarity (Figure 9). Out of 42 bases aligned, 28 bases match up perfectly without any deletion or substitution. The A-T content of the promoter element is 83% which is comparable to the sequences of other pox-virus promoters (Weir and Moss, 1983; Mars and Beaud, 1987; Lee-Chan et al, 1988). Besides this similarity, there are no remarkable DNA elements within the promoter region, upstream of RNA start site.

LITERATURE CITED

1. Moss, B. and Flexner, C., (1987) Annu. Rev. Immunol. 5, 305-324.
2. Coupar, B.E.H. et al. (1986) Eur. J. Immunol. 16, 1479-1487.
3. Moss, B. (1985) In: Virology (Fields, B.N. ed.) pp. 685-703. Raven Press. N.Y. and London.
4. Davis, L.G. et al. (1986) Basic method in molecular biology, Elsevier Science Publishing, N.Y.
5. Herman, G.E. et al. (1986) Nucleic Acids Res. 14, 7130
6. Chakrabarti, S. et al. (1985) Mol. Cell. Biol. 5, 3403-3409
7. Miller, J.H. (1972) Experiments in molecular genetics. Cold Spring Harbour Laboratory, Cold Spring Harbour, N.Y.
8. Smith, G.L. et al., (1984) Biotech. Genet. Engg. Rev. 2, 383-407
9. Hanggi, M. et al., (1986) EMBO J. 5, 7071-1076
10. Rosel, J.L. et al., (1986) J. Virol. 60, 436-449.
11. Weir, J.P. and Moss, B. (1983) J. Virol. 46, 530-537
12. Mars, M. and Beaud, G. (1987) J. Mol. Biol. 198, 619-631
13. Lee-Chen, G.J. et al., (1988) Virology 163, 64-79

TABLE 1

Approx. sizes of early transcripts hybridizing to four PstI fragments of FPV genome. Total cellular RNA isolated from FPV infected cells in presence of AraC was hybridized on northern blots to nick translated cloned PstI fragments of the FPV genome.

PROBE	PstI fragment and its size (kb)	Approx. sizes of early transcripts (kb)
pTT55	E (20.5)	2.0, 1.7, 1.2 and 0.8
pTT63	F (17.3)	3.2, 2.3, 1.3 and 1.0
pTT28	J (12.5)	3.5, 2.4 and 1.7
pTT68	M (5.7)	Not detected

TABLE 2

Activity of B-galactosidase in plasmid constructs in VV-transient expression system. E and L are Early and late promoter elements respectively and Δ represent mutations (see below). Transient expression experiments were carried out according to Chakrabarti et al (1985) using CV-1 cells and 25 ug of plasmid DNA. B-gal activity assayed by the method of Miller (1972) is expressed as umol of ONP produced/ 3×10^6 cells/30 min at 28°C. The values represent mean of three estimations from the same experiment.

pSK08 was generated by deleting the ClaI/PstI fragment of PSK08. In pSK09 two bases, (CT) near the RNA start site (TACTAAATG) have been deleted creating TAAAATG sequence (Figure 8).

Plasmid Construct		B-gal activity	
		-AraC (Late)	+AraC (Early)
pSK 08	(LacZ - E)	35.78	50.75
pSK 08	(LacZ - E Δ)	0.13	0.00
pSK 09	(LacZ - L)	6.50	0.27
pSK 09	(LacZ - L Δ)	0.27	0.00
pSK 08	(no virus infection)	0.00	0.01

TABLE 3

Activity of B-galactosidase in plasmid constructs containing VV or FPV promoters in VV transient expression system. E and L are early and late elements of FPV promoter. Plasmids pSK20, 22 and 24 also contain a CAT gene opposite to LacZ. For details see text and Figure 8. Experimental details are as in Table 2. B-gal activity is expressed as μmol of ONP produced/ 3×10^6 cells/30 min at 28°C .

Plasmid Construct		B-gal activity	
		- AraC (Late)	+AraC (Early)
pSK 18	(LacZ - E, FPV-TK)	25.10	34.44
pSK 20	(LacZ - E, VV-TK)	26.70	32.50
pSK 22	(LacZ - E, FPV-TK)	24.50	29.40
pSK 24	(LacZ - L, FPV-TK)	4.6	0.27
pTP4	(LacZ - P7.5, VV-TK)	7.2	0.4
pDB22-LacZ	(LacZ-PL11, FPV-TK)	24.8	0.27
pSK 22	(no virus)	0.03	0.01

Finally, it is to be understood that various other modifications and/or alterations may be made without departing from the spirit of the present invention as outlined herein.

1. A gene sequence including a first promoter for the expression of a major early fowlpox virus protein.
2. A gene sequence according to claim 1 further including a second promoter for the expression of a late fowlpox virus protein in opposite orientation to said first promoter.
3. A DNA sequence according to claim 2 of approximately 40 base pairs in length, containing both promoter elements in opposite orientation to each other.
4. A plasmid including
 - a plasmid cloning vector; and
 - a gene sequence including
 - a first promoter for the expression of a major early fowlpox virus protein; and
 - a second promoter for the expression of a late fowlpox virus protein in opposite orientation to said first promoter.
5. A plasmid according to claim 4 wherein the plasmid cloning vector is selected from plasmids pUC8, pUC12, M13-mp8 and M13-mp9.
6. A plasmid selected from plasmids pSK06 and pSK07 as hereinbefore described.
7. A viral vector including a
 - portion of the genome of a vector virus;
 - a gene sequence including
 - a first promoter for the expression of an early fowlpox virus protein; and
 - a second promoter for the expression of a late fowlpox virus protein in opposite orientation to said first promoter; and

a first DNA sequence coding for a first foreign gene of interest and under the control of the first promoter.

8. A viral vector according to claim 1 wherein the first foreign DNA sequence codes for a first antigen characteristic of an avian disease.

9. A viral vector according to claim 7 further including alternatively or in addition to said first DNA sequence a second DNA sequence coding for a second foreign gene of interest and under the control of the second promoter.

10. A viral vector according to claim 9 wherein the second foreign DNA sequence codes for a second antigen characteristic of an avian disease.

11. A viral vector according to claim 7 wherein the portion of the genome of a virus is a portion of the fowlpox virus genome or vaccinia virus genome.

12. A vaccine including a viral vector according to claim 11.

13. A process for the preparation of a viral vector which process includes

providing

a viral DNA from a fowlpox virus; and

a plasmid cloning vector;

constructing a genomic library from the viral DNA;

identifying a gene sequence from the genomic DNA library, said gene sequence including

a first promoter for the expression of a major early fowlpox virus protein; and

a second promoter for the expression of a late fowlpox virus protein in opposite orientation to said first promoter; and

inserting the gene sequence into a suitable site in the plasmid cloning vector.

14. A gene sequence according to claim 1, substantially as hereinbefore described with reference to any one of the accompanying drawings.




FIG 1

2/10




FIG 2

3/10

10	20	30	40	50	60
GGTCCTAAAT	TTTGGTGGAT	AAGGCAAATT	ACTGCTTTGT	TGATTGTTAA	ATCTATTAAG
70	80	90	100	110	120
AAAACCTGGTA	AAAATACCAG	CAGTATCGTT	ACTACGTAAT	ATAGATATCA	TTCTATCCTG
130	140	150	160	170	180
AATAGACCTA	CTATCGTCTG	TATTGTATTC	<u>GTCTACTATA</u>	<u>GATTCCTTCT</u>	<u>CATTTCTACT</u>
			AccI	PRIMER 4	
190	200	210	220	230	240
ATCATCTTCA	TCTAGCTTTT	CTGAAAATAT	CTCTGGATTA	TTACTAACAT	TACGTTTGAT
250	260	270	280	290	300
TCTAGAAATA	AAATCTTTGT	GGAAGTTCTC	<u>AGCCATTTAG</u>	TATCCTAAAA	TTGAATTGTA
			ORF3		
310	320	330	340	350	360
<u>ATTATCGATA</u>	<u>ATAAATGGAC</u>	AATTCTATGG	ATATTAACGA	TATACTACTG	TCAGATGATA
ClaI	ORF2				
370	380	390	400	410	420
ACGATTATAA	GAGTTACGAT	GAAGATGATG	ACTCTATATC	<u>CGATATAGGA</u>	<u>GAAACAAGTG</u>
				PRIMER 3	
430	440	450	460	470	480
ATGATTGTTG	TACGACTAAA	CAATCGGATT	CCAGGATAGA	ATCTTTCAAG	TTCGATGAAA
490	500	510	520	530	540
CTACTCAATC	ACCTCATCCA	AAACAATTGA	GCGAAAGGAT	AAAGGCTATA	AAACAACGAT
550	560	570	580	590	600
ACACTAGACG	TATAAGCCTA	TTTGAAATAA	CTGGAATTTT	ATCCGAAAGT	TATAATTTAT
610	620	630	640	650	660
TACAACGTGG	<u>AAGAATTCCA</u>	TTACTTAATG	ACCTGACAGA	AGAAACGTTT	AAAGATTCAA
	EcoRI				
670	680	690	700	710	720
TTATTAATAT	TATGTTTAAA	GAAATAGAAC	AAGGAAATTG	TCCTATAGTT	ATACAAAAGA
730	740	750	760	770	780
ATGGAGAACT	TTTATCCTTA	ACCGACTTTG	ATAAAAAAGG	AGTACAGTAT	CATCTGGACT
790	800	810	820	830	840
ACATTAAAAC	TATATGGCGT	AACCAACGTA	<u>AATTATAATT</u>	TAGATATATA	ATGTTCTTGA
			ORF1	ORF2	
850	860	870	880	890	900
ATAAAATCGA	<u>ATATGAATTC</u>	TATATCTACA	GCATTTTCTT	TATAGTTAAT	GTTGTAATTA
	EcoRI				
910	920	930	940	950	960
TCGGTTATAC	ATTGAACAAT	TGATATAAGT	GTTGTTTGT	GCTTTTCATA	TTCTTCCACA
970	980	990	1000	1010	1020
AATATGTTTT	TATACATTTT	ACGGTTATTT	GATATCTCAC	TTATCAATCC	CTGAATGTTA
1030	1040	1050	1060	1070	1080
TTAACCTTTC	TTTTCTTTAA	ATCTTCTACG	GAAACTTTAG	TCTTAAATGA	TGCCATTATT
1090	1100	1110	1120	1130	1140
TCACTAAAAA	GAACGTGTAA	GCGTTCGTTA	GTAAGTATTT	CAGAATACAC	TATACTAGAG

FIG 3

SUBSTITUTE SHEET

4/10

```

      1150      1160      1170      1180      1190      1200
AGTTTAGAAA ATATGTTAAC AAATTGTGTT GTTTTGACAC AGCTAGTTTG AAATAAAATA

      1210      1220      1230      1240      1250      1260
ATATTAGGTA ATACCTTTTT AAAGAAGCTT ACGTATTTAT TATTTATCTG GTCTATACCG

      1270      1280      1290      1300      1310      1320
TCTATCGTTA TATCGCAGAA ACACTTAATA CCAAATATTA CGTTTTCTTT AGAGAAAGAA

      1330      1340      1350      1360      1370      1380
AATACATCTT TATATTCTTC AAGTTTTATC TTATCAGATA CTACATCTGT ATTAAAAAGT

      1390      1400      1410      1420      1430      1440
GCAATTATCT TTATGATATA ATTGCTATCC GCTAGGACTT TATTTATTGT TCTGATAATG

      1450      1460      1470      1480      1490      1500
AAACTATTGT TTTCCATTAA TATTTTGTA GCTTGATGTT CGTTATTAGC ACTTTTAATT

      1510      1520      1530      1540      1550      1560
AACGACACAA TTCCTAGTAT CTTTTTTAAA TCCTGCACTA TTTCATTTGT ATCTTTTTTTC

      1570      1580      1590      1600      1610      1620
ATATTAGAGT ACATATTGTT TATAGATGTA ATAACTTTTG CATATACTAA CATATCTTTA

      1630      1640      1650      1660      1670      1680
AATATTCTGA TAAACTGTTC TTTTGTTTCT TTATCTGTTA TTTTGTTGAG CATAGATTTT

      1690      1700      1710      1720      1730      1740
ACGTTTGCCG CTGATCGCAT ATACCAAAT GTAAACATCT TGAATTCTAC TTGCTGCATG
              PRIMER 2
      1750      1760      1770      1780      1790      1800
GCTAGAATAA CAGTCTCGTC AGACATTGCG CAGTTAATAT CACCGCCTAT CTTACTTTCT
              PRIMER 1
      1810      1820      1830      1840      1850      1860
AGAATAGGAA AAACCGTTAA AAATGAATCG ATATCATAT CATAATTAC TTCATACACT
              Cla I
      1870      1880      1890      1900      1910      1920
TTTTGACCTG TACTATTCTC TAAATACTTC TTACTTAATT CATAAAATTC AATAAATGCA

      1930      1940      1950      1960      1970      1980
TTCCTGA ACT TTTCCATGAT TTATAGCTTG TAGTATTTTT CTAATATTGA TTTGATTTGT
              ORF1
      1990      2000      2010      2020      2030      2040
ATATGTGTAT AATCTTTACC GATACCTAAT TTAAGCATAG TATTAATAAC CCAAGTTTTT

      2050      2060      2070      2080      2090      2100
ATAAATATTT CTTTGTTATC GGTTACCACA TATTTAAATA CTGAATTAAA GTATTTAACT

      2110      2120      2130      2140      2150      2160
ATAGGATTAT TCTGAGTAGA TATATTATCC ATAAATACAG ACCGTTTTGT AGATAGAGGT

      2170      2180
TCTGTAAATA ATTCACCGTC GAC
              Sal I

```

FIG 3 (cont.)

SUBSTITUTE SHEET

5/10




FIG 4

6/10




FIG 5




FIG 6




FIG 7




FIG 8

10/10

5'-A	T	T	T	A	G	T	A	T	C	C	T	A	A	A	A	T	T	G	A	A	T	T	G	T	A	A	T	T	A	T	C	C	A	T	A	A	T	→	Early			
5'-A	T	T	T	A	T	T	A	T	C	G	A	T	A	A	T	T	A	C	A	A	T	T	C	A	T	T	T	T	T	A	G	G	A	T	A	C	T	A	A	T	→	Late

FIG 9

INTERNATIONAL SEARCH REPORT

International Application No PCT/AU 89/00055

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁴ According to International Patent Classification (IPC) or to both National Classification and IPC Int. Cl. ⁴ C12N 15/00, 7/00, C07H 21/04, A61K 39/275 // (C12N 7/00, C12R 1:91)														
II. FIELDS SEARCHED <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Minimum Documentation Searched ⁷</div> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 25%; border-bottom: 1px solid black;">Classification System</th> <th style="border-bottom: 1px solid black;">Classification Symbols</th> </tr> <tr> <td style="text-align: center; vertical-align: middle; padding: 10px;">IPC</td> <td style="padding: 10px;">WPI, WPIL, Keywords : Fowlpox, Avianpox, USPA Vaccinia</td> </tr> </table> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁶</div> <p style="padding: 10px;">AU: IPC C12N 15/00; GENBANK, EMBL, NBRF Figure No 9. CHEMICAL ABSTRACTS Keywords: Fowlpox, Avianpox</p>			Classification System	Classification Symbols	IPC	WPI, WPIL, Keywords : Fowlpox, Avianpox, USPA Vaccinia								
Classification System	Classification Symbols													
IPC	WPI, WPIL, Keywords : Fowlpox, Avianpox, USPA Vaccinia													
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁵ <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 10%; border-bottom: 1px solid black;">Category ⁸</th> <th style="border-bottom: 1px solid black;">Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²</th> <th style="width: 10%; border-bottom: 1px solid black;">Relevant to Claim No. ¹³</th> </tr> <tr> <td style="vertical-align: top; padding: 5px;">A</td> <td style="padding: 5px;">AU,B, 23424/84 (570940) (UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY UNITED STATES DEPARTMENT OF COMMERCE) (MOSS et al) 18 June 1984 (18.06.84)</td> <td></td> </tr> <tr> <td style="vertical-align: top; padding: 5px;">A,P</td> <td style="padding: 5px;">AU,A, 13766/88 (NIPPON ZEON CO, LTD) (YANAGIDA et al) 29 September 1988 (29.09.88)</td> <td></td> </tr> <tr> <td style="vertical-align: top; padding: 5px;">A,E</td> <td style="padding: 5px;">AU,A, 22228/88 (NIPPON ZEON CO, LTD) (YANAGIDA et al) 16 March 1989 (16.03.89)</td> <td></td> </tr> </table>			Category ⁸	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	A	AU,B, 23424/84 (570940) (UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY UNITED STATES DEPARTMENT OF COMMERCE) (MOSS et al) 18 June 1984 (18.06.84)		A,P	AU,A, 13766/88 (NIPPON ZEON CO, LTD) (YANAGIDA et al) 29 September 1988 (29.09.88)		A,E	AU,A, 22228/88 (NIPPON ZEON CO, LTD) (YANAGIDA et al) 16 March 1989 (16.03.89)	
Category ⁸	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³												
A	AU,B, 23424/84 (570940) (UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY UNITED STATES DEPARTMENT OF COMMERCE) (MOSS et al) 18 June 1984 (18.06.84)													
A,P	AU,A, 13766/88 (NIPPON ZEON CO, LTD) (YANAGIDA et al) 29 September 1988 (29.09.88)													
A,E	AU,A, 22228/88 (NIPPON ZEON CO, LTD) (YANAGIDA et al) 16 March 1989 (16.03.89)													
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>⁹ Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"G" document member of the same patent family</p> </div> </div>														
IV. CERTIFICATION <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;"> Date of the Actual Completion of the International Search 30 May 1989 (30.05.89) </td> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;"> Date of Mailing of this International Search Report 15 June 1989 (15.06.89) </td> </tr> <tr> <td style="border-bottom: 1px solid black; padding: 5px;"> International Searching Authority Australian Patent Office </td> <td style="border-bottom: 1px solid black; padding: 5px;"> Signature of Authorized Officer <div style="display: flex; align-items: center;"> <div>JOHN G. HANSON</div> </div> </td> </tr> </table>			Date of the Actual Completion of the International Search 30 May 1989 (30.05.89)	Date of Mailing of this International Search Report 15 June 1989 (15.06.89)	International Searching Authority Australian Patent Office	Signature of Authorized Officer <div style="display: flex; align-items: center;"> <div>JOHN G. HANSON</div> </div>								
Date of the Actual Completion of the International Search 30 May 1989 (30.05.89)	Date of Mailing of this International Search Report 15 June 1989 (15.06.89)													
International Searching Authority Australian Patent Office	Signature of Authorized Officer <div style="display: flex; align-items: center;"> <div>JOHN G. HANSON</div> </div>													